Epocrates, Inc. (Epocrates) is a provider of mobile drug reference tools and electronic health records to healthcare professionals and interactive services to the healthcare industry. As of December 31, 2011, its user network consists of well over one million healthcare professionals, including approximately 340,000, or more than 50% of United States physicians. The Company offers its products on major United States mobile platforms, including Apple iOS, Android and BlackBerry. Epocrates operates in two segments: Subscriptions and Interactive Services, and Electronic Health Records. It uses brand names include DocAlert, Epocrates, Epocrates Honors, Epocrates ID, Epocrates Lab, Epocrates MedTools, Epocrates Rx, Epocrates Rx Pro, Epocrates Dx, Epocrates QuickSurvey, Epocrates QuickRecruit, Epocrates MedInsight, EssentialPoints and MedCafe. In October 2011, it launched a redesign of the drug reference tool to create a new platform that provides healthcare professionals.
Industry, Sector and Symbol:
- Sector: N/A
- Industry: N/A
- Sub-Industry: N/A
- Symbol: NASDAQ:EPOC
- CUSIP: N/A
- Web: N/A
- Trailing P/E Ratio:
- P/E Growth:
Frequently Asked Questions for Epocrates (NASDAQ:EPOC)
What is Epocrates' stock symbol?
Epocrates trades on the NASDAQ under the ticker symbol "EPOC."
Who are some of Epocrates' key competitors?
Some companies that are related to Epocrates include Orange Belgium (MBSRF), Apple (AAPL), Alphabet (GOOGL), Alphabet (GOOG), Microsoft Corporation (MSFT), Amazon.com (AMZN), Facebook (FB), Premier Foods Spon (PRRFY), Berkshire Hathaway (BRK-A), Nestle SA (NSRGY), Industrial & Cmrcl Bnk f China Ltd (IDCBY), RDS-A (RDS-A), Roche Holding (RHHBY), Comcast Corporation (CMCSA), Intel Corporation (INTC), Cisco Systems (CSCO), Amgen (AMGN) and LVMH Moet Hennessy Louis Vuitton SE (LVMUY).
How do I buy Epocrates stock?
Shares of Epocrates can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Epocrates' stock price today?
MarketBeat Community Rating for Epocrates (NASDAQ EPOC)MarketBeat's community ratings are surveys of what our community members think about Epocrates and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Epocrates stock can currently be purchased for approximately $11.73.
Consensus Ratings for Epocrates (NASDAQ:EPOC) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Epocrates (NASDAQ:EPOC)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Epocrates (NASDAQ:EPOC)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Epocrates (NASDAQ:EPOC)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Epocrates (NASDAQ:EPOC)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Epocrates (NASDAQ:EPOC)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Epocrates (NASDAQ:EPOC)
Latest Headlines for Epocrates (NASDAQ:EPOC)
No headlines for this company have been tracked by MarketBeat.com
Epocrates (EPOC) Chart for Thursday, July, 20, 2017